TABLE 3.

Molecular targeted drugs with very high DSS₃ values

		TNBC		ER+HER2−		HER2+
Drugs	Reported targets	BC3	BC9	BC4	BC11	BC6	BC16
Bortezomib	20S proteasome NFkB Induces ERK phosphorylation to suppress cathepsin B	84	61		68		68
Romidepsin	HDAC1, HDAC2, HDAC3, HDAC3, HDAC8	75		73	61	68	77
Dinaciclib	CDK1, CDK12, CDK2, CDK5, CDK9	66					70
Panobinostat	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	63		62
YM155	BIRC5	71	83				85
ENMD-2076	AURKA, FGFR1, FGFR2, KDR, RET	66
Torin 2	MTOR	65		60		65
Sodium phenylbutyrate	Histone deacetylase	84	62		63
Alisertib	AURKA		86				88
AUY922	HSP90		62
17-DMAG	HSP90		66				66
Trametinib	MAP2K1, MAP2K2			63
Sapanisertib	MTOR, RICTOR			66		71
Poziotinib	EGFR, ERBB2, ERBB4					64
Elesclomol	HSP90					75	62
AZD8055	MTORC1, MTORC2					66	60
Delanzomib	26S mammalian proteasome						63